 Connection
Catherine Derington to Cardiovascular Diseases
This is a "connection" page, showing publications Catherine Derington has written about Cardiovascular Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.016 |
|
|
|
-
Derington CG, Berchie RO, Greene T, Jacobs JA, Moran AE, Xu Y, Narita K, Zheutlin AR, Cohen JB, Shimbo D, Bress AP. Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. J Am Coll Cardiol. 2025 Oct 28; 86(17):1437-1448.
Score: 0.390
-
Lu AD, Chavez C, Daugherty SL, Dhar P, Derington CG, Everhart R, Morse EF, Novins-Montague S, Trinkley KE, Waughtal JM, Zucker R, Carey E, Bull S, Peterson PN, Ho PM. Using artificially intelligent text messaging to improve health behaviors to reduce cardiovascular risk: study protocol for a pragmatic randomized control trial. Trials. 2026 Feb 20; 27(1).
Score: 0.100
-
Zhang F, Bryant KB, Moran AE, Zhang Y, Cohen JB, Bress AP, Sheppard JP, King JB, Derington CG, Weintraub WS, Kronish IM, Shea S, Bellows BK. Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study. J Am Heart Assoc. 2024 01 16; 13(2):e032370.
Score: 0.086
-
Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 01 02; 13(1):e032413.
Score: 0.086
-
King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB. New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc. 2023 09 05; 12(17):e030311.
Score: 0.084
-
Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress AP. Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020. J Clin Lipidol. 2023 Sep-Oct; 17(5):688-693.
Score: 0.084
-
Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. 2023 05 01; 8(5):443-452.
Score: 0.082
-
Derington CG, King JB, Bryant KB, McGee BT, Moran AE, Weintraub WS, Bellows BK, Bress AP. Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. Curr Hypertens Rep. 2019 11 07; 21(12):91.
Score: 0.064
-
Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu S. Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2120-2130.
Score: 0.023
-
Bress AP, Greene T, Derington CG, Shen J, Xu Y, Zhang Y, Ying J, Bellows BK, Cushman WC, Whelton PK, Pajewski NM, Reboussin D, Beddu S, Hess R, Herrick JS, Zhang Z, Kolm P, Yeh RW, Basu S, Weintraub WS, Moran AE. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. J Am Coll Cardiol. 2021 04 27; 77(16):1977-1990.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|